Aktarım Tamamlandı — 

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Abstract Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes include...

詳細記述

保存先:
書誌詳細
主要な著者: Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2022-04-01
シリーズ:Blood Cancer Journal
オンライン･アクセス:https://doi.org/10.1038/s41408-022-00668-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料